Six-month patient-reported outcome (PRO) results from AQUARiUS, a prospective, observational, multicenter phase 4 study in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving abiraterone acetate + prednisone (AAP) or enzalutamide (ENZ).

Antoine Thiery-Vuillemin,Mads Hvid Poulsen,Louis-Marie Dourthe,Redas Trepiakas,Edouard Lagneau,Elias Pintus,Dominique Beal Ardisson,Alison J. Birtle,Guillaume Ploussard,Hervé Besson,Martin Lukac,Paul Robinson,Alison Helen Reid

Six-month patient-reported outcome (PRO) results from AQUARiUS, a prospective, observational, multicenter phase 4 study in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving abiraterone acetate + prednisone (AAP) or enzalutamide (ENZ).

2018

Antoine Thiery-Vuillemin
Mads Hvid Poulsen
Louis-Marie Dourthe
Redas Trepiakas
Edouard Lagneau
Elias Pintus
Dominique Beal Ardisson
Alison J. Birtle
Guillaume Ploussard
Hervé Besson
Martin Lukac
Paul Robinson
Alison Helen Reid

5058Background: AQUARiUS is an ongoing study of PROs and medical resource use in chemotherapy-naive pts with mCRPC newly initiated on AAP or ENZ in a real-world setting. Initial 3-month (mo) subset...

Keywords:

Patient-reported outcome
Urology
Abiraterone acetate
Observational study
Prostate cancer
Physical therapy
Enzalutamide
Castration
Prednisone
Medicine
Oncology
in patient
castration resistant
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations